Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 19/20 | 0.80 |
| ▸ | CDK2 | P24941 | 19/20 | 0.80 |
| ▸ | CCNA1 | P78396 | 19/20 | 0.80 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.77 |
| ▸ | STK10 | O94804 | 1/20 | 0.77 |
| ▸ | LATS1 | O95835 | 1/20 | 0.77 |
| ▸ | PAK4 | O96013 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | NQO2 | P16083 | 1/20 | 0.77 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.77 |
| ▸ | MARK3 | P27448 | 1/20 | 0.77 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.77 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.77 |
| ▸ | PRKCI | P41743 | 1/20 | 0.77 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.77 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.77 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.77 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23377989 | 0.88 | CHEK1 (0.71) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL22676250 | 0.88 | CHEK1 (0.71) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL14564837 | 0.88 | CHEK1 (0.71) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL15146157 | 0.88 | CHEK1 (0.71) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11931021 | 0.88 | CHEK1 (0.71) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL10380123 | 0.87 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL17466881 | 0.87 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL2408669 | 0.87 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11931022 | 0.86 | CHEK1 (0.72) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11931033 | 0.86 | CHEK1 (0.72) | CHEK1CCNA2CDK2CCNA1RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730734-B2 | Use of ATR and Chk1 inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-22 | — | — | US | disclosed |
| US-9345705-B2 | Compositions and methods for treating cancer | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| US-8993535-B2 | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140343071-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. | 2014-11-20 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | CHEK1 2/4885CCNA2 85/4885CDK2 10/4885 |
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CDC25A, CDC25B | CHEK1 4/4885CCNA2 100/4885CDK2 10/4885 |
| US-20140343071-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | WEE1, WEE2, CHEK1 | CHEK1 3/4885CCNA2 424/4885CDK2 154/4885 |
| US-11730734-B2 | Use of ATR and Chk1 inhibitor compounds | CHEK1, ATR, CHEK2 | CHEK1 1/4885CCNA2 472/4885CDK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.